EyePoint Pharmaceuticals EYPT 深 沪
等待开盘 11-27 09:30:00 美东时间
14.79
+0.050
+0.34%
华盛通- 最 高14.96
- 今 开14.50
- 成交量 85.03万股
- 最 低 14.2601
- 昨 收 14.74
- 总市值 11.94亿
- 52周最高 14.96
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 3.91
- 委 比 -86.38%
- 总股本 8075.33万
- 历史最高 39.40
- 量 比 0.78
- 振 幅 4.75%
- 历史最低 2.19
- 每 手 1
- 风险率 2.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EyePoint Pharmaceuticals Receives Positive Phase 3 Trial Update
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On November ...
11-19 20:28
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals granted 7 new employees non-statutory stock options to purchase up to 31,000 shares under NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $11.58, vest over four years and have a 10-year term. EyePoint focuses on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU in Phase 3 trials for wet AMD and DME.
11-17 12:00
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
RBC Capital Maintains Outperform on EyePoint Pharmaceuticals, Raises Price Target to $39
RBC Capital analyst Lisa Walter maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and raises the price target from $28 to $39.
11-06 23:54
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals announced that its management will participate in three upcoming conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conference on November 10, 2025; Stifel 2025 Healthcare Conference on November 12, 2025; and Jefferies London Healthcare Conference on November 17, 2025. The company is focused on developing innovative therapeutics for serious retinal diseases, particularly with its lead product candidate, DURAVYU™, ...
11-03 12:00
EyePoint files automatic mixed securities shelf
EyePoint Pharmaceuticals (NASDAQ:EYPT) filed automatic mixed securities shelf. Filing More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School...
10-15 04:27
EyePoint Pharmaceuticals Initiates Pivotal Phase 3 Program For DURAVYU To Treat Diabetic Macular Edema; Expects First Patient Dosage In Q1 2026
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
10-15 04:03
EyePoint Announces Proposed Public Offering of Common Stock
EyePoint Pharmaceuticals announced an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million. The offering aims to fund clinical development of DURAVYU™ for wet AMD and DME, with proceeds also supporting other pipeline initiatives. The transaction is subject to market conditions, with more details available via the SEC. EyePoint is focused on innovative treatments fo...
10-14 20:35
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
DURAVYU™, developed by EyePoint Pharmaceuticals, has entered Phase 3 trials for treating diabetic macular edema (DME) with first patient dosing expected in Q1 2026. The active drug, vorolanib, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, targeting the multifactorial nature of DME. Preclinical data supports multi-mechanism efficacy, aligning with Phase 2 results showing early and sustained visual improvements. ...
10-14 20:01
